Impulse - Meeting Healthcare Pioneers: Recent Episodes
Mathieu Chaffard
Impulse invites listeners to meet the people shaping the current medical advancements through in-depth conversations about their field of expertise and the journey that took them where they are now. The podcast aims to democratize ongoing advances in medical technology and to introduce listeners to some of its key actors.
Wearables are a form of technology that has rapidly become a part of our lives over the past 15 years, with the introduction of devices from Fitbit, Apple, Samsung, and others to the market. Initially informing us about our heart rate and daily step count, they have evolved to incorporate increasingly sophisticated features, allowing us to track our sleep relatively accurately, monitor our overall physical activity, and sometimes even include recognized medical functions (such as the FDA-approved atrial fibrillation detection of the Apple Watch). However, no device of this type allows for real-time quantification of molecules circulating in our blood or other bodily fluids, through optical methods. And that's exactly the challenge that Leo and his team at Spiden have set for themselves: to create the most advanced wearable, capable of continuously and non-invasively measuring multiple biomarkers circulating in our bodies. This could redefine our understanding of our own physiology and change our approach to medicine, by providing insights for the prevention, diagnosis, and monitoring of several conditions, that were previously inaccessible. Since its creation in 2017, Spiden has been operating away from the spotlight, but Leo does us the honor in this exclusive episode to reveal the first secrets behind Spiden’s technology. We discuss its functioning, its initial applications, who the future users will be, and also the incredible team of world-renowned scientists Leo has managed to bring together in the fields of optics, electronic engineering, and machine learning (three fields that were originally completely foreign to him) to achieve his vision. A fascinating conversation about the future of personalized medicine with a bold and successful entrepreneur!
Timeline:
03:43 - Leo’s background as a serial entrepreneur from fintech to deep tech
04:56 - Why Leo found Spiden and works towards improving our health
07:14 - The mission of Spiden
11:00 - The technology behind Spiden
14:47 - The biomarkers that Spiden can track
19:02 - Target users of Spiden’s future wearable
22:28 - Designing a health-dedicated device
24:10 - Attracting world talents in fields you are not initially from
34:01 - The importance of in-person interactions in a scientific and multidisciplinary team
What we also talked about with Leo:
Continuous glucose monitoring (Abbott Freestyle Libre)
Bits & Pretzels HealthTech
Photoplethysmography (PPG)
Biohacking
Glucose Goddess
Whoop
Oura
Garmin
Huberman Lab
induced pluripotent stem cells (iPSCs)
We cited with Leo some of the past episodes from the series:
4 - Filtering the blood with nanoengineered beads - Lukas Langenegger - Hemotune
11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio
21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia
You can learn more about Spiden through their website. Feel free to follow as well their activities on LinkedIn! As mentioned by Leo during the episode, you can learn about the painful history of non-invasive glucose measurement through the book “The Pursuit of Noninvasive Glucose - Hunting the Deceitful Turkey” by John L. Smith. If you want to get in touch with Leo, feel free to contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 There’s now a bi-monthly newsletter around the podcast where you will be informed of the latest episodes and kept up to date on the latest medical tech progress, simply subscribe here! And don’t forget to follow our activities on LinkedIn and our website!
To discover the whole episode type "#23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden" on your streaming platform.
Given the rapid progress made in this field in recent years, autonomous vehicles could soon become part of our daily lives, bringing with them all the consequences and questions they raise in terms of modern mobility. This would benefit people with visual impairments who are unable to drive. However, it wouldn't necessarily assist them in their pedestrian moves, which will always play a significant role in their daily lives. Maël Fabien became aware of the lack of available solutions in this regard during a walk in town. He noticed a visually impaired person video calling a friend, who was guiding her through his voice based on the video she was sharing. As a result, he took inspiration from the latest advances in autonomous vehicles to create a harness capable of continuously analyzing the pedestrian environment, and safely guiding its users in all their movements. From there, Biped was born, a device that promises to improve the life of the 270 million visually impaired people worldwide, by providing them with a much more accurate and secure perception of their environment than traditional solutions.
In this surprising episode, you will learn about:
The daily life of a visually impaired person and its impact on mobility
How Biped was developed in close collaboration with its end users
Some key concepts of autonomous mobility and the sensors that constitute it
How Biped translates the user's 3D environment into audio cues for guidance
The potential applications of Biped beyond ophthalmology
An outlook on the future of mobility and what it might change for those with limited vision!
Timeline:
02:01 - Maël’s interests at the interface of economics and speech processing
04:07 - Addressing the need for 270 million visually impaired
07:50 - What Biped is about
15:32 - How Biped reads and translates the environment of the user
22:30 - How users are trained on the system
24:14 - The spectrum of visually impaired people that Biped serves
30:08 - The underlying business model
32:19 - Potential applications beyond ophthalmology
34:58 - What users say about it
39:09 - Maël’s definition of impact
What we talked also talked about with Maël:
Idiap Research Institute
Mobility training
Lidar
Bone conduction headphones
Jules Gonin Eye Hospital
Glaucoma
Retinitis Pigmentosa
Macular Degeneration
Cochlear Implants
You can learn more about Biped.ai through their website. Feel free to follow as well their activities on LinkedIn! As mentioned by Maël during the episode, you can find out more about the latest advances in autonomous driving and related AI through Tesla’s yearly AI Day (2022 recording here). He also recommends The Blind Life YouTube channel to understand how it feels to be in the shoes of a visually impaired person. If you want to learn more about Maël and his other endeavors besides Biped.ai, have a look at his blog! If you want to get in touch with Maël, feel free to contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 And don’t forget to follow our activities on LinkedIn and through our website!
To discover the whole episode type "#22 - Harnessing self-driving technology to guide the visually impaired - Maël Fabien - Biped.ai" on your streaming platform.
Few companies can claim to be a step ahead of tech giants in the wearable race. The Swiss company Aktiia can. They were the first to successfully bring to market a device capable of continuously and accurately measuring blood pressure, officially approved in Europe and soon to be in the US. All in a discreet bracelet that resembles a traditional jewel. It changes the game for how we approach hypertension, the first chronic condition worldwide affecting a staggering 1.4 billion people, and which comes with dire long-term consequences like strokes and heart attacks. The impact such groundbreaking technology can have on the daily lives of those affected is immense, not to mention its benefits for those in charge of their medical care. Say goodbye to the uncomfortable and cumbersome inflatable cuff (the actual “gold standard” to measure blood pressure), not to mention the major step forward in terms of design! Aktiia has defied expectations by merging optical and machine learning expertise over nearly two decades of cutting-edge research, resulting in a significant breakthrough in the world of wearables. In this new episode of the series, we sit with Jay Shah - the leading cardiologist and current Chief Medical Officer at Aktiia - who shares with us the story and functioning behind this stunning piece of technology. You will learn about:
Hypertension and the public health crisis it represents
The benefits of continuous blood pressure measurement
How the Aktiia bracelet works
How a small company like Aktiia was able to stand up to the biggest tech companies
Preventive medicine and why empowering patients in their self-care matters
A fascinating episode exploring the medical potential of wearables in our lives!
Timeline:
02:30 - Jay’s background as a cardiologist and what led him to Aktiia
05:30 - The most common cause of cardiovascular diseases: hypertension
10:15 - What Aktiia is about and what it changes for blood pressure monitoring
15:50 - How Aktiia’s technology work
20:12 - The limits of the pattern-matching approach with wearable data
24:00 - Why Aktiia succeeded where big tech companies failed
27:45 - Who can get access to Aktiia’s bracelet
30:35 - How Aktiia empowers patients to take better control of their condition
What we also talked about with Jay:
Mattia Bertschi
Josep Sola
Massachusetts General Hospital
Mayo Clinic
Blood pressure cuff (sphygmomanometer)
Photoplethysmography
NextMed Health
We cited with Jay some of the past episodes from the series:
1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens
12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health
You can learn more about Aktiia through their website. Feel free to follow their activities on LinkedIn, Twitter, and Instagram! As mentioned by Jay during the episode, you can find out more about the clinical research in hypertension and all the evidence developed around the bracelet in that regard here. For a very technical deep dive into cuffless blood pressure monitoring, we invite you to consult “The Handbook of Cuffless Blood Pressure Monitoring: A Practical Guide for Clinicians, Researchers, and Engineers” by Josep Sola himself, one of the founders from Aktiia. If you want to get in touch with Jay, feel free to contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 And don’t forget to follow our activities on LinkedIn and through our website!
To discover the whole episode type "#21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia" on your streaming platform.
Restoring one of our five senses, in this case, touch. The stakes are immense (1 in 1000 people are affected yearly by a peripheral nerve injury!) and the origins are diverse: traumatic accident, cancer, amputation, and many others. And solutions to this problem have long needed to be improved. Karen Zaderej and her team at Axogen have set themselves the goal of changing this situation, by proposing new ways of treating nerves, taking advantage of their regenerative potential. A chemical engineer by training, Karen began her career at Johnson & Johnson in its surgical solutions subsidiary, ETHICON. With 17 years of experience in roles ranging from manufacturing to product development and sales, she decided to leave her corporate career behind. In 2006 she joined a Floridian start-up in its infancy, developing a new type of medical device enabling nerves to regenerate, still at the prototype stage and not yet tested on humans. The outcome? A company that has become a world leader in the development of cutting-edge nerve repair solutions, listed on the stock exchange and now employs over 400 people. In this new episode, we delve into the world of peripheral nerves, the source of our physical and motor sensations, and their formidable regenerative capacities.
You will learn about:
How our nerves work and current approaches to repairing them
Phantom pain, how to explain it, and how to treat it
How women today can regain sensation in their breasts following a mastectomy
The journey of a remarkable woman entrepreneur who has made addressing nerve damage her life mission
Prepare to be nervously amazed as we unravel the secrets of touch restoration!
Timeline:
00:03:00 - Karen’s background as a nerve evangelist
00:07:35 - Key evolutions in medical technology that Karen witnessed
00:10:42 - What Karen learned at J&J that shaped the rest of her career
00:15:43 - What attracted Karen to Axogen and the potential of their technology
00:20:40 - Scaling up a medical device company from a very early stage onwards
00:23:15 - How Axogen enables nerve repair
00:27:18 - Bringing an answer to phantom pain
00:30:47 - The main indication areas covered by Axogen
00:38:31 - What the future of nerve repair might look like
What we also talked about with Karen:
Autograft
Allograft
Mastectomy
Neuroma
Da Vinci Surgical Systems
We cited with Karen some of the past episodes from the series:
6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore
2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical
You can learn more about Axogen through their website and their portfolio here. Feel free to follow as well their activities on LinkedIn, Twitter, and Facebook! As mentioned by Karen during the episode, you can find out more about clinical research in peripheral nerve repair through the complete library of published papers curated by the company. Karen also invites you to consult resensation.com and rethinkpain.com to hear about patient stories and find resources in case you face a similar situation. If you want to get in touch with Karen, feel free to contact her over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, feel free to do so contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! Follow also our activities on LinkedIn and through our website!
To discover the whole episode type "#20 - Restoring touch through nerve repair - Karen Zaderej - Axogen" on your streaming platform.
Developing a new drug is a tough and strenuous endeavour, requiring investments that go beyond $1 billion and sometimes up to 15 years of time. On top of that, only 1 out of 10 drug candidates successfully passes clinical trial testing and regulatory approval. The Dutch company Mimetas, specialized in the use of organ-on-a-chip technology, aims to address exactly this challenge by accelerating this laborious process and making it more predictable. Their expertise actually lies in the development of in-vitro human tissue models (including diseases) which recapitulate the cellular complexity but also the biochemical and mechanical cues that make up the real tissues from our body. Such models can then be used as a powerful experimental platform for drug discovery, since they reflect our actual biology so well. Bas Triestch is one of the three founders from Mimetas (alongside Jos Joore and Paul Vulto) who saw in the early 2010s the potential to leverage organ-on-a-chip methods at scale for the benefit of drug discovery, leading them to become the most innovative Dutch company in 2022! In this episode, Bas takes us behind the scenes of the fascinating science that they are driving at Mimetas, the impact that they are having on the R&D efforts from some of the biggest players in the biotech industry, but also the shift that they have operated as a company, starting as a “hardware” provider and gradually becoming a specialized scientific service firm.
Timeline:
01:35 - Bas’ background and the origins of Mimetas centered around new drug discovery approaches
05:31 - What organ-on-a-chip technology means and how it serves the development of new human tissue and disease models
09:05 - The OrganoPlate® as the key platform providing scalability and reproducibility for the study of such models
15:40 - Merging organoids and organ-on-a-chip technologies in a unique platform, the OrganoPlate® Graft
24:03 - Moving from better understanding diseases, through medication guidance, and up to personalized medicine
28:47 - Mimetas’ mission in accelerating the development of new treatments and finding the right drugs for the right patients
34:50 - Dealing with substantial amount of experimental data
39:24 - Shifting Mimetas’ business model from selling hardware components to offering specialized scientific services in the field of drug discovery
What we also talked about with Bas:
Leiden University
Hans Clevers
Roche
Galapagos
Trans-Epithelial Electrical Resistance (TEER)
Wnt signaling pathway
We cited with Bas some of the past episodes from the series:
5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore
8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche
As mentioned in the episode, you can learn more about Mimetas and the field of organ-on-a-chip engineering through their website. Based on Bas’ recommendation, we also invite you to check out this review to get a deeper understanding of the field and where it stands at the moment. If you want to get in touch with Bas, feel free to contact him per email at s.trietsch@mimetas.com or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram!
To discover the whole episode type “#13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas" on your streaming platform.
Daniel Kraft is a surprising and admirable figure in the digital health landscape. Originally trained as a physician in internal medicine and pediatrics, he then distinguished himself by his research work focusing on regenerative medicine, while at the same time initiating several entrepreneurial projects in the medtech space. RegenMed Systems is one of them, a company that he founded and which led him to create a new type of medical device to facilitate bone marrow harvest procedures. IntelliMedicine is another one, where he aims to create a system enabling patients to 3D print their own medication at home, avoiding the intake of multiple pills on a daily basis. Aside from his own entrepreneurial endeavours, he advises several Fortune-50 and digital health-related startups, and is on the board of Healthy.io. As one of the most renowned ambassadors of digital health, he is driven by the conviction that innovation in this space can only result from the synergies of disciplines and technologies that may initially be totally distant from the medical sphere. Through his activities at the Singularity University or through the program Exponential Medicine that he initiated, he brings together brilliant minds from a broad range of specialties who come together to explore convergent and rapidly developing technologies, to develop relevant applications in healthcare. Often called upon to speak to the future of health, medicine and technology, he has already given multiple TED and TEDMED Talks, and delivered keynotes to a wide array of organizations on those subjects. We talked with Daniel about his early days in the healthcare world, why he decided to study medicine and orient himself on this path, his perspective on the importance of collaboration and boldness when it comes to creating new digital health solutions, what the future looks like from his lens, but also how he manages to stay on top of things while keeping a healthy lifestyle!
Timeline:
00:59 - Daniel’s background moving from medical studies, through biomedical research, entrepreneurship and thought leadership in digital health
03:56 - What drove Daniel to start a career in healthcare
05:54 - How converging new digital technologies can benefit medical progress
09:00 - The shift in adoption within the medical community towards digital health
10:49 - The types of medical data available these days to advance our understanding and management of diseases
14:30 - Establishing a general database to reference all things digital health - Digital.Health
20:16 - Zooming in on RegenMed Systems and IntelliMedicine
26:25 - A lookout on Daniel’s potential future projects in healthcare
31:54 - Daniel’s tips and secrets on his (almost) endless source of energy and drive
What we also talked about with Daniel:
Bits & Pretzels HealthTech
Xolair
Stanford Byers Center for Biodesign
NASA
IBM Watson
CRISPR/Cas9
Continuum Health Ventures
Digitale Gesundheitsanwendungen (DiGA)
You can learn more about Daniel’s activities through his website (we recommend you to subscribe to his weekly newsletter), and you can follow him on LinkedIn and Twitter. For a deep-dive into digital health solutions, we recommend you to consult Digital.Health, the database that Daniel and his team put together and which regroups most of the solutions already available out there. In case you want to experience the thrill of digital health and share your ideas with some of the brightest minds in the field, check out NextMed.Health, the conference in San Diego curated by Daniel and his team from March 13 to 16 next year.
If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com And if you liked the episode, don’t hesitate to share it, subscribe to the podcast, leave a positive review on streaming platforms and follow our activities on LinkedIn, Instagram, Twitter as well as on our website!
To discover the whole episode type “#12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health" on your streaming platform.
Miniaturizing the lab to allow for the continuous analysis of proteins and hormones circulating in our body through a wearable. This is the aim of Xsensio - a Swiss startup developing the Lab-on-Skin(c) platform - which will enable in the future to continuously track compounds present in the interstitial fluid, right underneath our skin. It is in essence a similar concept as the established continuous glucose measurement devices (which are nowadays moving from pure medical applications to consumer-oriented wellness programs), the difference being the type of biomarkers that the Lab-on-Skin(c) platform will enable to monitor - proteins and hormones on-body, continuously and in real-time - opening applications ranging from cardiology to oncology, in the hospital setting or at home. Esmeralda Megally (CEO of the company) shares with us her vision around personalized medicine and which role the Lab-on-Skin(c) platform will play in this regard. With passion, she explains us the concepts behind the functioning of this surprising technology, what it takes to bring it to the market, and reveals the potential synergies that it may have in the future with the current wearables that are already part of our daily living.
Timeline:
02:20 - Esmeralda’s background and how it led to the creation of Xsensio
09:14 - The unmet need that Xsensio is addressing with its Lab-on-Skin(c) platform
13:51 - The applications where the Lab-on-Skin(c) platform will play a role
17:28 - The functioning of the Lab-on-Skin(c) platform and its components
22:50 - What lies ahead of Xsensio before making its first product commercialized
28:09 - Combining the Lab-on-Skin(c) platform with traditional wearables data
29:57 - Defining a medical product development roadmap in an emerging field and how to deal with accompanying uncertainty
What we also talked about with Esmeralda:
Fitbit
Apple Watch
Bill & Melinda Gates Foundation
Lab for Youth Mental Health
NANOLAB
Veri
Supersapiens
C-reactive protein
Troponin T
Mayo Clinic
Rea Diagnostics
We cited with Esmeralda some of the past episodes from the series:
4 - Fighting sepsis with nanoengineered beads to filter the blood - Lukas Langenegger - Hemotune
If you want to know more about Xsensio, we invite you to consult their website and follow their activities on LinkedIn or Twitter. As mentioned by Esmeralda in the episode, have a read at this paper from Nature Biotechnology if you want to know more about the field of biosensing. You can get in touch with Esmeralda through LinkedIn or by email: esmeralda.megally@xsensio.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram!
To discover the whole episode type “#11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio" on your streaming platform.
Most of us have already heard about blockchain technology, as well as many things about cryptocurrencies and how they are transforming traditional approaches in the field of finance. But what about its relevance to healthcare and the potential applications it may have in this space? Eberhard Scheuer is the President of the dHealth Foundation, a not-for-profit organization from Switzerland providing the infrastructure and tools to major stakeholders in healthcare to leverage blockchain technology. He takes us through the basic concepts around blockchain and guides us through the benefits and the applications it may have in this field, when it comes for instance to empowering patients in managing their own health and the data that accompanies it, creating transparency across the pharmaceutical supply chain, or even preserving the authenticity of medical test results! A fascinating exchange and good entry point for newcomers in the field of blockchain and web3 applied to healthcare!
Timeline:
02:21 - Eberhard’s background and his entry point in web3 concepts applied to healthcare
06:29 - What blockchain is about
11:12 - Applications of blockchain technology to healthcare and its benefits
21:51 - The example of Estonia with blockchain-enabled electronic health records and the efforts of big tech companies in that regard
25:58 - The reason behind the dHealth Foundation and monetizing health data
38:30 - The services provided by the dHealth Foundation to its partners
46:44 - Misleading ideas around blockchain applications in healthcare
What we also talked about with Eberhard
Bitcoin
Ethereum
The Swiss Tropical and Public Health Institute
Roche
Digital twin
Alex Cahana
If you want to know more about the dHealth Foundation, we invite you to consult their website and follow their activities on LinkedIn, Medium and Twitter. As mentioned by Eberhard in the episode, if you want to know more about the field of blockchain and the latest trends in that regard, have a look at Blockchain Revolution, Bloomberg Crypto, CoinDesk and Cointelegraph. You can get in touch with Eberhard through LinkedIn or by email: es@dhealth.foundation If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram!
To discover the whole episode type “#10 - Applying blockchain technology to healthcare - Eberhard Scheuer - dHealth Foundation" on your streaming platform.
Raimundo Sierra is the Founder and CEO from VirtaMed, a Swiss company specialized in surgical simulation systems, covering interventions in orthopaedics, gynecology, laparoscopy and urology, providing true-to-life training for aspiring surgeons and established ones, as part of their continuing education. At the edge of robotics and gaming, Raimundo takes us through the origins of this extremely ambitious project, explaining how the first systems from VirtaMed were developed, and how they currently fit in the diverse surgical curricula provided by established institutions in Europe, China and the US. Beyond the volume of training that such platforms can offer and the positive repercussions in terms of operative results, they also provide equitable access to surgical training, a point that is particularly close to Raimundo's heart given his personal experience.
Timeline:
01:36 - Raimundo’s background and what led him to the world of surgical simulation systems
07:33 - The origins of VirtaMed and what differentiates its solutions from medical devices
11:24 - How surgical simulation systems are integrated to medical curricula
16:16 - The components of VirtaMed surgical simulation systems
20:38 - VirtaMed’s global footprint and driving adoption of its products
24:58 - The potential of emerging technologies like machine learning in the field of surgical simulation
27:11 - How VirtaMed works with surgeons
34:47 - VirtaMed’s business model
What we also talked about with Raimundo:
Stefan Tuchschmid
AANA
AGA
Charité - Universitätsmedizin Berlin
B. Braun Melsungen AG
Bruno Schmied
Dieter Hahnloser
Melanie Aregger
Avelo
We cited with Raimundo some of the past episodes from the series:
2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical
7 - Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - Mindmaze
If you want to know more about VirtaMed, we invite you to consult their website and follow their activities on LinkedIn. As mentioned by Raimundo in the episode, you can learn more about the field of surgical simulations and the latest trends in that regard through the following sources:
Society for Simulation in Healthcare
The PROFICIENCY project
You can get in touch with Raimundo by email: raimundo.sierra@virtamed.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram!
To discover the whole episode type “#9 - Creating the Gran Turismo of surgery - Raimundo Sierra - VirtaMed" on your streaming platform.
Disclaimer: Nikolce and I both work for Roche, nevertheless all opinions expressed in this episode are our own and do not necessarily represent the position of our employer.
Nikolce is leading the Organoid Engineering Group at the Roche Institute for Translational Bioengineering. Organoids are miniaturised versions of the organs and tissues that make up our bodies, sharing phenotypic and genetic aspects of them. They carry a lot of hope in terms of applications in healthcare, from the replacement of animal testing involved in the assessment of drug safety and efficacy, to personalized medicine where they can be leveraged to inform the treatment most suitable to a particular patient, or in terms of potential transplants to address certain diseases. We exchanged with Nikolce on the what, the how and the why behind this fascinating field of bioengineering, which tremendously developed over the past years. He takes us through the current status of the technology and the clinical applications it has already demonstrated, and shares his view on how the field will evolve in the future.
Timeline:
03:13 - Mandate and ambition of the Roche Institute for Translational Bioengineering
06:18 - What organoids are and from which tissues they are derived
09:53 - Reprogramming cells’ fates from tissues and deriving induced pluripotent stem cells
11:05 - Growing organoids in vitro and related challenges
13:50 - Applications leveraged at the ITB and the types of tissues at stake
15:55 - Refining the biology and turning the theoretical promises around organoids into practice
20:38 - Towards the use of organoids as human grafts or replacing animal testing
22:37 - Organ-on-a-chip technologies and how they complement organoids
26:17 - Synergies with bioprinting technologies and the challenges that come along with building tissue replicas
28:03 - Looking back at the main advancements since the first organoids came out and their ability to recapitulate features proper to a patient
33:56 - The ethical framework around the use of organoids
37:38 - Moving from Academia to the Industry as a scientist
What we also talked about with Nikolce:
Matthias Lütolf
Hans Clevers
Mina Bissell
Celeste M. Nelson
Nathalie Brandenberg
Silke Hoehnel
Sun Bioscience
Cellink
Embryonic stem cells
HeLa cells
If you want to learn more about the Roche Institute for Translational Bioengineering, we encourage you to consult their website. As mentioned by Nikolce during the episode, the Harvard Stem Cell Institute and Stem Cell Technologies are two information sources worth checking out in case you want to take a deep-dive into what organoids are, and go further into the topics we discussed with him. If you want to reach out to Nikolce, you can contact him over LinkedIn. If you liked the episode, please share it, rate it and leave a 5 star review on Apple Podcasts! You can find more about the podcast through its dedicated website or follow our activities on LinkedIn and Instagram. If you want to give me feedback on this episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com.
Disclaimer: Nikolce and I both work for Roche, nevertheless all opinions expressed in this episode are our own and do not necessarily represent the position of our employer.
To discover the whole episode type “#8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche” on your streaming platform.
Naveed Ejaz is VP Product Strategy and Clinical Development (formerly Director of Digital Therapies) at MindMaze, the very first unicorn from Switzerland, pioneering the fascinating field of digital neurotherapeutics. Underneath these fluffy terms lies the concept of “software-as-a-medicine”, where pieces of code come together to drive a behavioural intervention, enabling patients suffering from neurological diseases to improve their condition. In the area of neurology where pharmaceutical and medical device solutions have been limited, this field opens up promising perspectives in terms of extended care delivery, stronger engagement from patients towards their treatment plans, and facilitated care coordination. We talked with Naveed about how video games could be leveraged to create an engaging therapy for the benefits of patients suffering from neurological diseases, the challenges that companies involved in the field of digital therapeutics face, MindMaze’s vision to build an integrated platform delivering cutting-edge rehabilitation programs for patients, and why all of that is not purely about technology but rather engaging the patients as much as all healthcare professionals surrounding them. We also get a sneak peek at the activities led within MindMaze Labs, the R&D division of the company partnering with institutions like Formula One to understand better how the brain works under extreme situations!
Timeline:
04:43 - Naveed’s background and what drove him towards neuroscience and neurorehabilitation
13:03 - What digital neurotherapeutics are and what “software-as-a-medicine” entails
20:30 - Conceptual acceptability towards digital neurotherapeutics in healthcare
23:38 - The benefits of gamification in neurorehabilitation therapies
29:44 - How the rehabilitation therapies from MindMaze are designed
42:57 - The key characteristics of a therapeutic video game that keeps patients engaged
47:15 - Rehabilitating fine dextrous motion versus gross movement
52:04 - Naveed’s role as VP Product Strategy and Clinical Development (formerly Director of Digital Therapies)
55:03 - Initiatives led by MindMaze Labs R&D center and partnering with Formula One
What we also talked about with Naveed:
BrainGate
John Krakauer
Johns Hopkins University
MindMaze Labs
Formula One
If you want to know more about MindMaze, we invite you to consult their website and follow their activities on LinkedIn. As mentioned by Naveed in the episode, if you want to know more about the field of digital neurotherapeutics and the latest trends in that regard, have a look at Rock Health (and subscribe to their newsletter) and MobiHealthNews. You can get in touch with Naveed through LinkedIn or by email: naveed.ejaz@mindmaze.ch
If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram!
To discover the whole episode type "#7 - Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - MindMaze" on your streaming platform.
This is a special episode where we receive Saul Marquez, host of Outcomes Rocket, one of the leading podcast series in the healthcare space, having already interviewed key opinion leaders from the field throughout more than 1000 episodes! The format of the podcast is slightly different from the episodes produced so far as part of Impulse, with shorter conversations and a stronger business focus. The range of topics covered though is unprecedented: with testimonials from people working in the industry (from startups to big corporations), Academia, healthcare providers, or in insurance firms. It’s hard not to say that they’ve probably already covered all the potential topics the field may offer!
Outcomes Rocket is available at the following platforms:
Apple Podcasts
Spotify
Google Podcasts
Overcast
You can find out more about Outcomes Rocket through their website, we also invite you to follow their activities on LinkedIn and subscribe to their newsletter.
If you want to reach out to Saul, feel free to contact him through LinkedIn!
If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com.
And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms!
Bringing back mobility to those who lost it. This is the challenge that Jocelyne Bloch, neurosurgeon at the CHUV, together with the neuroscientist Grégoire Courtine from EPFL and their teams at .NeuroRestore and Onward set out to address. A decade after demonstrating that the technology developed by Prof. Courtine’s lab was able to bring back lower limb mobility to paraplegic rats, it has now been applied to humans in a research context through their joint work with phenomenal outcomes: most paraplegic patients implanted with the stimulation system they have developed were able to retrieve significant mobility of their lower limbs, enabling them to stand, walk and even climb stairs! Based on an electrode array coupled to a pulse generator (both fully implantable) remotely controlled, the system delivers selective stimulation of the spinal cord at the locations where the lower limb muscles are activated, in a sequence that replicates the mobility patterns that abled people demonstrate. Images of patients having experienced this technology, moving out of their wheelchair to stand and walk, have been seen throughout the world, and the hope that it brings for those concerned is immense, considering also the other applications that it could open for the rehabilitation of the upper limbs or for blood pressure regulation. In the latest episode from Impulse, we had the chance to sit down with Jocelyne and exchange with her on the infancy of this therapy, where she takes us through its working principle, the challenges that come along with bringing such a technology from the lab to the market, as well as on the life-changing benefits it may hold for patients in the future. With great humility, she also talks about how she manages to combine her clinical practice as a functional neurosurgeon, to leading a research group composed of over 80 collaborators, all of that while raising two children and with a husband at home!
Timeline:
05:20 - Jocelyne’s background and what led her to functional neurosurgery
08:18 - Approach taken to enable paraplegic rats to walk again and moving towards human applications
14:55 - The first human implantation
17:20 - Towards autonomous mobility renewal
18:25 - The STIMO study focusing on mobility and upcoming trials
21:03 - Managing expectations of patients
23:20 - Making a viable therapy with a reasonable rehabilitation training phase
26:17 - Leveraging potential synergies with exoskeletons
27:23 - Current technological constraints
28:34 - Origins and purpose of .NeuroRestore, and the close collaboration with Onward
33:03 - Towards upper limbs and hands rehabilitation therapies
34:10 - Retrieving sensory feedback thanks to the current therapy
35:23 - Adding brain-computer interaction layers to the current therapy
37:56 - Staying on top of things when working as a neurosurgeon, leading a clinical research center, and a family life
39:41 - Evolving as a woman in the field of neurosurgery
What we also talked about with Jocelyne:
Grégoire Courtine
Patrick Aebischer
Jean-Guy Villemure
Bogdan Draganski
Baroreflex
Neuroprosthetics
Neuroplasticity
EEG
ECoG
CHUV
UNIL
EPFL
Medtronic
Elon Musk
We cited with Jocelyne some of the past episodes from the series:
3 – Augmenting the lives of paraplegics with exoskeletons – Tristan Vouga – Twiice
5 – Transforming diagnostics through spatial biology – Déborah Heintze – Lunaphore
If you want to know more about .NeuroRestore, we invite you to consult their website. We also invite you to follow their activities on LinkedIn. If you are interested in learning more about the startup Onward, we invite you to check out their website as well as their LinkedIn page. You can contact Jocelyne by email: jocelyne.bloch@chuv.ch If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com.
To discover the whole episode type “#6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore” on your streaming platform.
Transforming our understanding of how our immune system works and how certain pathologies like cancer unfold: that is the mission to which Lunaphore has committed since 2014. Through a cutting-edge platform capable of accelerating complex staining and imaging procedures, the Swiss startup is pioneering what is now named “spatial biology”, recognized by the journal Nature as Method of the Year 2020. Applicable to many disease areas, the field carries great hopes in bringing to light new insights that will accelerate drug discovery and drive the development of personalized therapies in the long run. Its power resides in the possibility to analyze multiple biomarkers in parallel, while preserving the spatial properties of the tissue studied. Alongside Ata Tuna Ciftlik and Diego Dupouy, Déborah Heintze is one of the three co-founders of Lunaphore. She joined the adventure soon after the completion of her curriculum in biomedical engineering, the same day that an offer was made to her by a large company for a position that would have been synonymous with stability and comfort from the outset. The gamble paid off, as she now leads as Chief Marketing Officer the product and marketing efforts of the startup, which has been recognized many times as one of the most innovative and promising emerging companies in the Swiss ecosystem. She takes us through the origins of the project, explaining how the opportunity to co-found the startup arose, how the technology they developed functions, and how spatial biology will revolutionize the way we understand immunology and the promises it holds in the fight against many diseases.
Timeline:
01:50 - Déborah’s background and evolution within Lunaphore since its creation
04:48 - How Lunaphore emerged from a PhD thesis
06:49 - How the opportunity co-found a startup emerged
10:22 - What the technology from Lunaphore is about
12:27 - Paving the way of spatial biology for diagnostic purposes
16:48 - The promise that spatial biology holds in our understanding of pathologies like cancer and how Lunaphore is supporting it
20:04 - The features and functioning of LabSat® and COMET™
22:50 - Dealing with the analysis of large pathology data volumes
25:24 - Transitioning from research applications to clinical ones
27:50 - Deploying LabSat® and COMET™ in labs while making sure the onboarding remains flawless for users
29:29 - The time and efforts required to build these platforms from scratch up to their market launch
33:37 - Moving towards new applications and disease areas
35:08 - How the technology from Lunaphore is transforming the staining and imaging workflows from labs
38:39 - Evolving as a woman in the medical technology entrepreneurial sphere
What we also talked about with Déborah :
EPFL Technology Transfer Office
Harvard-MIT Health Sciences and Technology
CHUV
Spatial biology
Immunostaining
Microfluidics
Cytometry
Omics
DistalMotion
Sophia Genetics
We cited with Déborah some of the past episodes from “Impulse - Meeting Healthcare Pioneers”:
2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical
If you want to know more about Lunaphore, we invite you to consult their website. As mentioned in the episode, we strongly recommend you to check out their blog which aims to democratize spatial biology and all of its aspects in a simple yet informative manner. We also invite you to follow their activities on LinkedIn or through their newsletter (subscription link available through the company website).
You can contact Déborah through LinkedIn or by email: deborah.heintze@lunaphore.com
If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com.
And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms!
To discover the whole episode type "#5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore" on your streaming platform.
One consequence of the covid-19 crisis we are still going through is sepsis, a lethal misguided reaction of the immune system following an infection, currently responsible for 11 million deaths yearly on a global scale. Together with his team, Lukas Langenegger is addressing this life-threatening condition using a unique technology leveraging magnetic microscopic beads that enable the filtration of blood and the removal of toxic compounds circulating through the body during such a medical episode. The so-called Hemosystem is akin to a dialysis machine where the traditional membrane filter is replaced by a solution containing these beads. Offering a very large surface area, they are used to selectively trap key toxic compounds known to contribute to sepsis: their removal enables in fact to reestablish the immune balance of the patient, leading to drastically improved outcomes. This disruptive technology has been rewarded and praised multiple times in the Swiss medtech sphere and the media. Lukas himself has already been featured in the German issue of Forbes, as a recognition for the pioneering work and contribution that he and his team are bringing in the fight against this terrible condition. We exchanged with Lukas on his professional path, which started in the world of banking before moving towards chemical engineering and the start of a PhD, which he interrupted after a few months to embrace the entrepreneurial route. He guides us with passion through the genesis of Hemotune, the functioning of the system they have created and the surprising development perspectives that such a platform could allow, from the treatment of cancer up to the extension of our longevity!
Timeline:
(01:05) - Introduction to Lukas’ background and the origins of Hemotune
(02:12) - Transitioning from banking to chemical engineering
(04:59) - Quitting a PhD to become an entrepreneur
(07:34) - Bringing multiple specialties together to found Hemotune
(08:58) - Finding support from the Swiss ecosystem to kick start your own firm
(09:49) - Hemotune’s technology and its first indication: sepsis
(11:17) - Understanding the mechanisms of sepsis and the lack of current recovery treatment
(14:20) - Timing of the intervention for patients using the Hemosystem
(15:01) - Current standard of care and keeping patients suffering from sepsis alive
(16:22) - Reestablishing the immune balance thanks to the Hemosystem
(18:10) - Towards magnetic microscopic beads tailored to each patient
(19:56) - The Hemosystem workflow and blood filtering cycles
(20:57) - Engineering the magnetic microscopic beads
(22:30) - Preventing toxicity from the beads towards the blood
(26:00) - The development roadmap of the Hemosystem and its foreseen availability
(30:18) - Moving towards other indications (e.g. cancer, autoimmune diseases, longevity)
(32:02) - Establishing a new treatment modality at the interface of a drug and a medical device
(33:15) - Addressing the burden of antimicrobial resistance
What we also talked about with Lukas :
Carlos Andrea Mora
Corinne Hofer
Precision Medicine
ETHZ
MIT
Functional Materials Laboratory from Prof. Wendelin Stark
HLA-DR
Kurz Gesagt
Immune: A Journey into the Mysterious System That Keeps You Alive
Leo Grünstein
Spiden
If you want to know more about Hemotune, we invite you to consult their website: https://www.hemotune.ch/ We also invite you to follow their activities on LinkedIn or through their newsletter (subscription link available through the company website). You can contact Lukas through LinkedIn or by email: lukas.langenegger@hemotune.ch If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com
To discover the whole episode type "#4 - Fighting sepsis with nanoengineered beads to filter the blood - Lukas Langenegger - Hemotune" on your streaming platform.
Wearables bringing back the ability to walk for paraplegics: this is the world in which Tristan Vouga is evolving. Passionate by the field of robotics and willing to have an impact on society, he turned his PhD thesis into the Swiss startup TWIICE. The company is developing a modular exoskeleton, bringing back the ability for its users to stand, walk, climb stairs and even go on a ski tour! Beyond the technological achievement and the numerous awards it has won in international contests, their platform has the potential to transform the lives of many paraplegics as well as amputees. We talked with Tristan about his transition from PhD student to entrepreneur, about their exoskeleton capabilities, the feelings of “ownership, embodiement and agency” that are key to a seamless human-machine interaction, and about how innovation can be derived from science-fiction!
Timeline:
(01:44): Tristan’s introduction and background in wearable robotics
(03:22): Moving to the US to explore brain-controlled exoskeletons
(08:10): Description of the exoskeleton TWIICE, how it operates and supports paraplegics
(10:52): The importance of embodiment, ownership and agency in human-machine interactions
(12:42): Leveraging brain signals to control wearable exoskeletons
(14:03): Generating haptic feedback to enhance the feelings of ownership, embodiment and agency
(15:57): Developing an exoskeleton for ski touring
(18:38): Exploring new use cases for amputees
(21:01): Innovative commercial models to distribute the cost of ownership among patients
(22:59): A clinical trial to demonstrate the efficacy and safety of TWIICE in a community setting
(24:29): Seamless human-machine interaction as a key differentiator
(26:16): Moving towards an exoskeleton not requiring crutches
(30:20): The Cybathlon and competing against other exoskeletons
(35:02): Dealing with the frustration of access hurdles for patients
(36:11): Coping with the demand from patients while driving R&D efforts
(38:17): Transitioning from PhD student to entrepreneur
(40:18): Drawing inspiration from science-fiction
What we also talked about with Tristan:
EPFL
ETHZ
Duke University
ReHassist
The Nicolelis Lab
Neuralink
The triad: embodiment-ownership-agency
Boston Dynamics
The Cybathlon
The Global Innovation Challenge
Blade Runner
Testmate Health
We cited with Tristan some of the past episodes from the podcast:
1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens
If you want to know more about Twiice, we invite you to consult their website: https://twiice.ch/
You can contact Tristan through LinkedIn or by email: tristan.vouga@twiice.ch
If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com
To discover the whole episode type "#3 - Augmenting the lives of paraplegics with exoskeletons - Tristan Vouga - TWIICE" on your streaming platform.
Lucien Blondel is one of the leading figures in the field of surgical robotics, having already led the development of several platforms supporting orthopaedic, spinal and brain surgeries. Together with Quantum Surgical, which he co-founded alongside Bertin Nahum, Fernand Badano and Sophie Roca, they are addressing liver cancer through a new robotic platform supporting ablation procedures. Under the name of “Epione” (the goddess of care in the Greek mythology), it represents a breakthrough in this field, not only supporting surgeons in the execution of the ablation procedure, but also in the planning phase up to the validation of the surgical act. Through a combination of cutting-edge image processing technology, computer vision and haptics, Epione is on its way to revolutionize interventional oncology and improve access to liver cancer ablation, for patients and for surgeons. We exchanged with Lucien on his background, what brought him to surgical robotics, the specificities of this field, his role in leading the technical development of Epione, and its underlying promise in the cure of liver cancer.
Timeline:
(02:09) - Lucien’s introduction and background in surgical robotics
(04:51) - How he got into this field and what drove his interest to it
(07:43) - The uprising of surgical robotics and key developments over the past years
(14:16) - Identifying the right disease area and type of intervention
(20:02) - The type of cancer targeted by Epione and the surgical act it complements
(22:49) - Enabling percutaneous ablation beyond interventional radiologists
(25:02) - Applications of Epione beyond liver cancer
(27:20) - Epione’s components and workflow
(32:51) - Synchronizing the patient’s breathing to the robotic arm positioning
(35:43) - Synergies between Epione and other platforms previously developed by Lucien and his team
(38:22) - Moving towards fully autonomous surgical interventions
(41:20) - The meaning behind “Epione”
(43:11) - Suggested resources to dig deeper into surgical robotics
(45:34) - The “Why”
What we also talked about with Lucien:
ROSA
Epione
Mako Robotic-Arm Assisted Surgery
Versius Surgical Robotic System
Da Vinci Surgical Systems
ExcelsiusGPS
Gustave Roussy Institute
Mayo Clinic
The International Journal of Medical Robotics and Computer Assisted Surgery
If you want to know more about Quantum Surgical, we invite you to consult their website: https://www.quantumsurgical.com/
You can contact Lucien through LinkedIn or by email: l.blondel@quantumsurgical.com
If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com
To discover the whole episode type "#2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical" on your streaming platform.
Cardiovascular diseases represent the leading cause of deaths worldwide. Despite the permanent progress in the treatment of such conditions, targeted prevention approaches remain a key solution to address this issue. This is the challenge that Imageens, a Paris-based startup led by Ted Baldwin, is tackling through the application of artificial intelligence to medical imaging, with the aim to quantify your arterial age. This specific biomarker unvails unique opportunities to anticipate heart conditions for people at moderate risk, with the promise to inform better clinical care decisions. We exchanged with Ted on the burden that cardiovascular diseases represent on a global level, the power of AI applied to medical imaging to discover early indicators of these pathologies, and how these insights can drive better personalized prevention programs to stay away from them.
Timeline:
(01:50) - The origins of Imageens
(06:23) - The unmet need that Imageens is addressing
(08:53) - Existing cardiac risk scores and the arterial age concept
(13:10) - Technical approach to quantify the arterial age using MRI and AI
(15:41) - Relationship between biological and arterial ages
(20:32) - The MESA trial led by Johns Hopkins University and its link to the discovery of cardiac risk scores
(23:26) - Imageens softwares Artfun+ and LABEL, their functioning and role in predictive imaging biomarkers discovery
(30:21) - Moving beyond MRI to other imaging modalities
(31:35) - Target patient population and access to Imageens technology
(33:43) - Acceptance by physicians and the medical community
(36:48) - Patient journey description
(38:00) - Moving towards predictive analysis of the optimal cardiac prevention program
What we also talked with Ted about:
Assistance Publique - Hôpitaux de Paris (AP-HP)
MESA trial
Framingham risk score
Cardiac CT calcium score
Ascending aortic distensibility
Ted’s TEDx presentation
Ganymed Robotics
Zoï
Altos Labs
Qualitiso
If you want to know more about Imageens, we invite you to consult their website: https://www.imageens.com/
You can contact Ted through LinkedIn or by email: tbaldwin@imageens.com
If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com
To discover the whole episode type "#1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens" on your streaming platform.
Welcome to Impulse, the podcast where you will meet the people shaping the current medical advancements, through in-depth conversations about their field of expertise, and the journey that took them where they are now. Its aim is to democratize ongoing advances in medical technology, and introduce listeners to some of its key actors.